Comparison
BPC-157 vs. FOXO4-DRI
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Research other
CAS no.
137525-51-0
2074706-72-8
Molecular weight
1419.5 g/mol
3735 g/mol
Half-life
4 h
0.5 h
Sequence
GEPPPGKPADDAGLVD-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)Mechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Evidence base
Highest evidence
Animal model
Animal model
Studies
4
3
of which in humans
0
0
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
1